DHG.VN
Unloved QualityDHG Pharmaceutical Joint Stock Company · Healthcare · Vietnam · $420M cap · $29K/day traded
VND 82,500 +0.0% · close 6 Nov · scored 7 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 7 Nov 2026, the MoatMap Score for DHG Pharmaceutical Joint Stock Company (DHG.VN) is 96/100, ranked against 25,000+ stocks in 38 markets (Quality 87, Value 69, Momentum 49, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT DHG PHARMACEUTICAL JOINT STOCK COMPANY
Read
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam.
FINANCIAL SUMMARY (VND)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.7T | 5.0T | 4.9T | 5.3T | 4.0% | 5.3T | 5.4T | 5.7T | 3.9% |
| EPS (VND) | 7,318 | 7,780 | 5,763 | 6,308 | -4.8% | 6,710 | 6,741 | 7,140 | 6.4% |
| Shares | 130.7M | 130.7M | 130.7M | 130.7M | 0.0% | 130.7M | — | — | — |
| Debt | 114.7B | 604.7B | 682.5B | 32.6B | -34.3% | — | — | — | — |
| Equity | 4.3T | 4.9T | 4.1T | 4.1T | -1.2% | — | — | — | — |
| Op CF | 901.3B | 240.2B | 1.3T | 1.2T | 10.4% | 702.6B | — | — | — |
| Inv CF | -353.7B | -179.8B | -446.0B | 811.7B | — | — | — | — | — |
| Fin CF | -550.3B | -170.1M | -902.8B | -2.0T | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 99% of stocks we rank over the past year (volatility 10% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DHG.VN are excluded.
Peer medians: ROE 15.9% · P/E 18.7x · Gross margin 45.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.